Evidence map›Paper›PMID 34730265›Full record

ArticleEuropean journal of heart failure2022

Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia.

Matthew W Segar, Muhammad Shahzeb Khan, Kershaw V Patel, Muthiah Vaduganathan, Vaishnavi Kannan, Duwayne Willett, Eric Peterson, W H Wilson Tang, Javed Butler, Brendan M Everett and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. 2024 update in heart failure.ESC heart failure · 2025
    Review
  8. Review
  9. Artificial Intelligence to Diagnose Complications of Diabetes.Journal of diabetes science and technology · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Validation of the WATCH-DM and TRS-HFJournal of the American Heart Association · 2022
    Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Matthew W SegarDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-6100-0897
Muhammad Shahzeb KhanDivision of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Kershaw V PatelDepartment of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Muthiah VaduganathanBrigham and Women's Hospital Heart and Vascular Center, Department of Medicine, Harvard Medical School, Boston, MA, USA.
Vaishnavi KannanClinical Informatics Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Duwayne WillettDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Eric PetersonDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
W H Wilson TangDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Javed ButlerDivision of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Brendan M EverettBrigham and Women's Hospital Heart and Vascular Center, Department of Medicine, Harvard Medical School, Boston, MA, USA.
Gregg C FonarowDivision of Cardiology, Ronald Reagan UCLA Medical Center, Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, CA, USA.
Thomas J WangDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Darren K McGuireDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ambarish PandeyDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
The University of Texas Southwestern Medical Center · USBrigham and Women's Hospital · USDuke University · USCleveland Clinic · USHouston Institute for Clinical Research · USHouston Methodist · USRonald Reagan UCLA Medical Center · US

Funding

Evaluation of Racial Differences in Cardiorespiratory Fitness Decline with Aging & Underlying Biological MechanismsR03AG067960 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI PANDEY, AMBARISH · 2020 to 2021
$327k
NIA NIH HHS R03 AG067960
6 · The paper itself

Abstract

aimsTo evaluate the performance of the WATCH-DM risk score, a clinical risk score for heart failure (HF), in patients with dysglycaemia and in combination with natriuretic peptides (NPs). METHODS AND

resultsAdults with diabetes/pre-diabetes free of HF at baseline from four cohort studies (ARIC, CHS, FHS, and MESA) were included. The machine learning- [WATCH-DM(ml)] and integer-based [WATCH-DM(i)] scores were used to estimate the 5-year risk of incident HF. Discrimination was assessed by Harrell's concordance index (C-index) and calibration by the Greenwood-Nam-D'Agostino (GND) statistic. Improvement in model performance with the addition of NP levels was assessed by C-index and continuous net reclassification improvement (NRI). Of the 8938 participants included, 3554 (39.8%) had diabetes and 432 (4.8%) developed HF within 5 years. The WATCH-DM(ml) and WATCH-DM(i) scores demonstrated high discrimination for predicting HF risk among individuals with dysglycaemia (C-indices = 0.80 and 0.71, respectively), with no evidence of miscalibration (GND P ≥0.10). The C-index of elevated NP levels alone for predicting incident HF among individuals with dysglycaemia was significantly higher among participants with low/intermediate (<13) vs. high (≥13) WATCH-DM(i) scores [0.71 (95% confidence interval 0.68-0.74) vs. 0.64 (95% confidence interval 0.61-0.66)]. When NP levels were combined with the WATCH-DM(i) score, HF risk discrimination improvement and NRI varied across the spectrum of risk with greater improvement observed at low/intermediate risk [WATCH-DM(i) <13] vs. high risk [WATCH-DM(i) ≥13] (C-index = 0.73 vs. 0.71; NRI = 0.45 vs. 0.17).

conclusionThe WATCH-DM risk score can accurately predict incident HF risk in community-based individuals with dysglycaemia. The addition of NP levels is associated with greater improvement in the HF risk prediction performance among individuals with low/intermediate risk than those with high risk.

Indexed as

Heart FailureNatriuretic PeptidesAdultCohort StudiesGlucose Metabolism DisordersHumansRisk AssessmentRisk FactorsNatriuretic PeptidesBiomarkersDiabetesHeart failurePre-diabetesRisk predictionRisk stratification

Identifiers

PMID34730265
PMCPMC10535364
OpenAlexW3211129163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.